LLY

768.65

+0.45%↑

JNJ

150.16

+0.34%↑

NVO

69.32

-6.15%↓

ABBV

182.37

-1.44%↓

UNH

299.41

-0.81%↓

LLY

768.65

+0.45%↑

JNJ

150.16

+0.34%↑

NVO

69.32

-6.15%↓

ABBV

182.37

-1.44%↓

UNH

299.41

-0.81%↓

LLY

768.65

+0.45%↑

JNJ

150.16

+0.34%↑

NVO

69.32

-6.15%↓

ABBV

182.37

-1.44%↓

UNH

299.41

-0.81%↓

LLY

768.65

+0.45%↑

JNJ

150.16

+0.34%↑

NVO

69.32

-6.15%↓

ABBV

182.37

-1.44%↓

UNH

299.41

-0.81%↓

LLY

768.65

+0.45%↑

JNJ

150.16

+0.34%↑

NVO

69.32

-6.15%↓

ABBV

182.37

-1.44%↓

UNH

299.41

-0.81%↓

Search

Axsome Therapeutics Inc

Отворен

СекторЗдравеопазване

102.26 2.11

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

99.7

Максимум

101.98

Ключови измерители

By Trading Economics

Приходи

15M

-59M

Продажби

2.7M

121M

EPS

-1.216

Марж на печалбата

-48.914

Служители

712

EBITDA

14M

-57M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+78% upside

Дивиденти

By Dow Jones

Следващи печалби

4.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-346M

5.1B

Предишно отваряне

100.15

Предишно затваряне

102.26

Настроения в новините

By Acuity

4%

96%

1 / 381 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

Axsome Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

20.06.2025 г., 18:52 ч. UTC

Печалби

Accenture Shares Fall on Bookings Decline, Concerns over Federal Government Contract -- 3rd Update

22.06.2025 г., 23:59 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Worries Over Middle East Conflict -- Market Talk

22.06.2025 г., 23:55 ч. UTC

Пазарно говорене

Markets Wait to See if Iran's Response Will be Symbolic or Substantial -- Market Talk

22.06.2025 г., 23:51 ч. UTC

Пазарно говорене

Oil Climbs After U.S. Attack on Iran's Nuclear Sites -- Market Talk

22.06.2025 г., 23:43 ч. UTC

Пазарно говорене

Reasons to Believe Strait of Hormuz Will Remain Open -- Market Talk

22.06.2025 г., 23:38 ч. UTC

Пазарно говорене

Nikkei May Fall as Middle East Uncertainty Persists -- Market Talk

22.06.2025 г., 23:11 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

22.06.2025 г., 23:11 ч. UTC

Пазарно говорене

Early Market Reaction to Iran Attacks Restrained -- Market Talk

22.06.2025 г., 22:59 ч. UTC

Пазарно говорене

Gold, Silver Rise as Investors Seek Haven After Strikes on Iran -- Market Talk

22.06.2025 г., 21:43 ч. UTC

Пазарно говорене

Australian Govt Says Supports US Strikes On Iran -- Market Talk

21.06.2025 г., 08:20 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

21.06.2025 г., 08:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

21.06.2025 г., 08:20 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

20.06.2025 г., 20:50 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

20.06.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

20.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

20.06.2025 г., 20:13 ч. UTC

Печалби
Придобивния, сливания и поглъщания

These Stocks Moved the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

20.06.2025 г., 20:11 ч. UTC

Пазарно говорене

Natural Gas Slides in Late-Week Profit Taking -- Market Talk

20.06.2025 г., 19:56 ч. UTC

Пазарно говорене

Crude Oil Slips to End Week -- Market Talk

20.06.2025 г., 18:35 ч. UTC

Пазарно говорене

Warehouse Clubs Seen Growing Market Share -- Market Talk

20.06.2025 г., 18:12 ч. UTC

Пазарно говорене

Gold Slides to Close Shortened Week -- Market Talk

20.06.2025 г., 17:56 ч. UTC

Пазарно говорене

Baker Hughes Reports Slight Decrease in U.S. Rig Count -- Market Talk

20.06.2025 г., 17:50 ч. UTC

Печалби
Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

20.06.2025 г., 17:35 ч. UTC

Придобивния, сливания и поглъщания

Cisco Was the Dot-Com Bust's Biggest Loser. Now It's at a 25-Year High. -- Barrons.com

20.06.2025 г., 17:30 ч. UTC

Пазарно говорене
Печалби

Adobe's AI Headwinds Seen Fading -- Market Talk

20.06.2025 г., 17:03 ч. UTC

Печалби

Accenture Earnings Beat Expectations. Why the Stock Is Falling Anyway. -- Barrons.com

20.06.2025 г., 16:50 ч. UTC

Пазарно говорене
Печалби

Global Equities Roundup: Market Talk

20.06.2025 г., 16:50 ч. UTC

Пазарно говорене
Печалби

Accenture Seeing Companies Shift to Leapfrog Mentality -- Market Talk

20.06.2025 г., 16:44 ч. UTC

Придобивния, сливания и поглъщания

Meet QXO, the Upstart Building Materials Stock That May Battle Home Depot for GMS -- Barrons.com

20.06.2025 г., 16:40 ч. UTC

Пазарно говорене
Печалби

Accenture Can't Yet Estimate Longer Term Impact from Federal Cuts -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Axsome Therapeutics Inc Прогноза

Ценова цел

By TipRanks

78% нагоре

12-месечна прогноза

Среден 179.23 USD  78%

Висок 210 USD

Нисък 148 USD

Според 16 анализатори от Wall Street, предложили 12-месечна ценова цел за Axsome Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

16 ratings

16

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

107.24 / 112.29Подкрепа & съпротива

Краткосрочен план

Weak Bearish Evidence

Средносрочен план

Neutral Evidence

Дългосрочен план

Strong Bullish Evidence

Настроение

By Acuity

1 / 381 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.